Anti-vascular endothelial growth factor therapy for ocular neovascular disease
- 1 November 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Opthalmology
- Vol. 18 (6), 502-508
- https://doi.org/10.1097/icu.0b013e3282f0ca54
Abstract
Recent research has shown that vascular endothelial growth factor (VEGF) is responsible for many ocular pathologies involving neovascularization. Over the past several years several new agents targeting VEGF have become commercially available for intraocular use. These agents have revolutionized the care of neovascular age related macular degeneration and have great potential for other blinding conditions such as diabetic retinopathy, retinopathy of prematurity, and neovascular glaucoma. The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial first showed that an anti-VEGF agent (pegaptanib) was able to prevent vision loss in neovascular age related macular degeneration. The Minimally Classic/Occult Trial of Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trials showed that ranibizumab prevented moderate vision loss in neovascular age related macular degeneration and for the first time that a substantial proportion of patients regained vision. Smaller case series have shown that bevacizumab can regress retinal, iris and disc neovascularization. Ongoing trials are investigating the utility of anti-VEGF therapy in retinopathy of prematurity, diabetic retinopathy, and neovascular glaucoma. Newer anti-VEGF therapies have shown unprecedented efficacy in treating age related macular degeneration with many patients experiencing improvement in vision. Ongoing trials will help guide their use in age related macular degeneration and expand their indications to many other blinding diseases.Keywords
This publication has 40 references indexed in Scilit:
- Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eyeExperimental Eye Research, 2007
- A Novel Vascular Endothelial Growth Factor Receptor 2 Inhibitor, SU11248, Suppresses Choroidal NeovascularizationIn VivoJournal of Ocular Pharmacology and Therapeutics, 2006
- Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose StudyOphthalmology, 2006
- The Effect of Ruboxistaurin on Nephropathy in Type 2 DiabetesDiabetes Care, 2005
- Effect of Ruboxistaurin on Blood–Retinal Barrier Permeability in Relation to Severity of Leakage in Diabetic Macular EdemaInvestigative Ophthalmology & Visual Science, 2005
- Angiogenic Pathways in Diabetic RetinopathyThe New England Journal of Medicine, 2005
- The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic RetinopathyDiabetes, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2004
- Use of Soluble Recombinant Decoy Receptor Vascular Endothelial Growth Factor Trap (VEGF Trap) to Inhibit Vascular Endothelial Growth Factor ActivityClinical Colorectal Cancer, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004